Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project.
van Gils MPMQ., Stenman UH., Schalken JA., Schröder FH., Luider TM., Lilja H., Bjartell A., Hamdy FC., Pettersson KSI., Bischoff R., Takalo H., Nilsson O., Mulders PFA., Bangma CH.
An overview is given of serum and urine prostate cancer markers that are currently under investigation and subsequently the P-Mark project is introduced. There are many markers showing promise to overcome the limitations of prostate specific antigen (PSA). Eventually, these markers should be able to increase the specificity in diagnosis, differentiate between harmless and aggressive disease and identify progression towards androgen independence at an early stage. In the P-Mark project, several recently developed, promising markers will be evaluated using clinically well-defined biorepositories. Following successful evaluation, these markers will be validated on a sample set derived from two large, European, prostate cancer studies and used for the identification of special risk groups in the general population. In addition, novel markers will be identified in the same biorepositories by different mass spectrometry techniques.